- Home
- MDXH vs IGMS Comparison
MDXH vs IGMS Comparison
Compare MDXH & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- IGMS
- Stock Information
- Founded
- MDXH 2003
- IGMS 1993
- Country
- MDXH Belgium
- IGMS United States
- Employees
- MDXH N/A
- IGMS N/A
- Industry
- MDXH
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- IGMS Health Care
- Exchange
- MDXH Nasdaq
- IGMS Nasdaq
- Market Cap
- MDXH 84.6M
- IGMS 82.1M
- IPO Year
- MDXH 2021
- IGMS 2019
- Fundamental
- Price
- MDXH $2.18
- IGMS $1.31
- Analyst Decision
- MDXH Buy
- IGMS Hold
- Analyst Count
- MDXH 1
- IGMS 8
- Target Price
- MDXH $6.00
- IGMS $6.00
- AVG Volume (30 Days)
- MDXH 67.5K
- IGMS 897.9K
- Earning Date
- MDXH 08-20-2025
- IGMS 08-13-2025
- Dividend Yield
- MDXH N/A
- IGMS N/A
- EPS Growth
- MDXH N/A
- IGMS N/A
- EPS
- MDXH N/A
- IGMS N/A
- Revenue
- MDXH $94,507,000.00
- IGMS $2,681,000.00
- Revenue This Year
- MDXH $23.51
- IGMS $134.30
- Revenue Next Year
- MDXH $17.68
- IGMS $22.37
- P/E Ratio
- MDXH N/A
- IGMS N/A
- Revenue Growth
- MDXH 25.46
- IGMS 27.36
- 52 Week Low
- MDXH $1.35
- IGMS $0.92
- 52 Week High
- MDXH $3.50
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- MDXH 58.07
- IGMS 57.18
- Support Level
- MDXH $2.13
- IGMS $1.12
- Resistance Level
- MDXH $2.32
- IGMS $1.26
- Average True Range (ATR)
- MDXH 0.12
- IGMS 0.08
- MACD
- MDXH 0.01
- IGMS 0.00
- Stochastic Oscillator
- MDXH 76.19
- IGMS 86.54
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.